Amer. Soc. of Clinical Oncologists daily updates
I'm cross-posting this in the hopes that others interested, who don't already know about ASCO, check it out. The daily posts review much of the newest study results dealing with myriad types of cancer. And subscribing is free.
Established in 2010, The ASCO Post, in partnership with the American Society of Clinical Oncology (ASCO), communicates news of evidence-based multidisciplinary cancer care to a broad audience of oncology professionals and ASCO members.
To subscribe, goto:
One suggestion. Keep up to date with developments relevant to cancers issues of personal importance. And make note of the senior study designers. There might come a time when you'll want to learn more and want to contact them. (Or find out whom they consider experts about a certain drug or protocol.)
And here's just a small sample of today's articles:
1. FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
2. Long-Term Outcomes With Adjuvant Goserelin and Tamoxifen in Premenopausal Estrogen Receptor–Positive Breast Cancer
3. Research Shows Poor Patient Comprehension of Terms Commonly Found in Electronic Health Information
“One of the things that was really surprising was we asked on the survey whether the respondent is a health-care worker, but the data showed that being one didn’t correlate with better understanding of medical terms,” Dr. Verosky said."